These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11157657)

  • 41. [Clopidogrel should be added to aspirin for at least 1 year after percutaneous coronary interventions (CREDO) while before them its loading dose can reach 600mg (ISAR-COOL)].
    Gratsianskiĭ NA
    Kardiologiia; 2003; 43(5):71-3. PubMed ID: 12942928
    [No Abstract]   [Full Text] [Related]  

  • 42. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
    Münzel TF; Post F
    Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S215-8. PubMed ID: 17109252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The value of selectivity.
    Colombo A; Stankovic G
    J Am Coll Cardiol; 2006 Feb; 47(4):719-20. PubMed ID: 16487834
    [No Abstract]   [Full Text] [Related]  

  • 45. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
    J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
    Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
    Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bivalirudin.
    Warkentin TE; Greinacher A; Koster A
    Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 51. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty.
    Fischman DL; Savage MP
    JAMA; 1997 Aug; 278(6):518-9. PubMed ID: 9256229
    [No Abstract]   [Full Text] [Related]  

  • 52. Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors.
    Kokolis S; Cavusoglu E; Clark LT; Marmur JD
    Prog Cardiovasc Dis; 2004; 46(6):506-23. PubMed ID: 15224257
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Debate of adjunctive pharmacology for percutaneous coronary intervention: thrombin inhibitors and clopidogrel are enough.
    Yehudai L; Feit F
    J Interv Cardiol; 2006 Oct; 19(5):464-9. PubMed ID: 17020572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antithrombotic therapy during percutaneous coronary interventions].
    Verheugt FW; Dieker H; Aengevaeren WR
    Ned Tijdschr Geneeskd; 2005 Apr; 149(17):912-6. PubMed ID: 15884403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eptifibatide in percutaneous coronary intervention. A review.
    Dery JP; O'Shea JC; Tcheng JE
    Minerva Cardioangiol; 2002 Oct; 50(5):531-46. PubMed ID: 12384635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What have We learned from ESPRIT? What will we learn from TARGET?
    Ferguson JJ
    J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.
    Lucking AJ; Newby DE
    Expert Opin Pharmacother; 2007 Apr; 8(6):759-76. PubMed ID: 17425472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
    Feldmann C; Deutsch HJ
    Dtsch Med Wochenschr; 2005 Jan; 130(1-2):29-30. PubMed ID: 15619171
    [No Abstract]   [Full Text] [Related]  

  • 59. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
    Brodie BR
    Catheter Cardiovasc Interv; 2008 May; 71(6):816-21. PubMed ID: 18412079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes.
    Jennings LK; Saucedo JF
    Curr Opin Cardiol; 2008 Jul; 23(4):302-8. PubMed ID: 18520712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.